Professor Berman is a pioneer in the development of recombinant vaccines for AIDS and other infectious diseases. His research interests include the development of vaccines, therapeutics, and diagnostics for the prevention and treatment of infectious diseases, as well as the development of new technology for commercial production of complex recombinent glycoproteins.
Published in Nature
Human immunodeficiency virus type 1 (HIV-1, HTLV-III/LAV), the retrovirus responsible for acquired immune deficiency syndrome (AIDS), shows a high degree of genetic polymorphism, particularly in the env gene. We have examined sera from rabbits and guinea pigs immunized with gp130, a recombinant env glycoprotein, and sera from HIV-1-infected subject...
Published in Journal of Cellular Biochemistry
Full-length (membrane bound) and truncated (secreted) forms of the beta 2 integrin heterodimer, CD11b/CD18 (Mac-1), were expressed in a human kidney cell line (293) that normally does not express leukocyte adhesion molecules (Leu-CAMs). The biosynthesis of recombinant Mac-1 in 293 cells differed from that reported for leukocytes in that heterodimer...
